FROM MALARIA TO MACULOPATHY: AN UNUSUAL BILATERAL CSCR PRESENTATION
International Journal of Advanced Research · 31.05.2026 · 14 (05) · 808-813
DOI: 10.21474/ijar01/23483 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Advanced Research, online erschienen am 31.05.2026. Verfasst von Neha Meena und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction:Central Serous Chorioretinopathy (CSCR) is characterized by serous detachment of the neurosensory retina and typically affects young to middle-aged males. It is rarely seen in young females and may follow systemic illnesses such as malaria. Early diagnosis can be difficult when classical fundus changes are absent. Material and Methodology: A 20 year old female presented to the out patient department of the ophthalmology department of Maharani Laxmi Bai Medical College, Jhansi with the complaint of mild blurring of vision and perception of distorted lines in both eyes since last 10 days.With history of Malaria positive,following the administration of chloroquine,the patient developed macular changes that were subsequently diagnosed as acute Central serous Chorioretinopathy based on optical coherence tomography findings. A detailed ocular and systemic examination was performed.
Zitieren
APA
Meena, N., Kumar, J., Gupta, S., & Goynka, Y. (2026). FROM MALARIA TO MACULOPATHY: AN UNUSUAL BILATERAL CSCR PRESENTATION. International Journal of Advanced Research, 14(05), 808-813. https://doi.org/10.21474/ijar01/23483
Vancouver
Meena N, Kumar J, Gupta S, Goynka Y. FROM MALARIA TO MACULOPATHY: AN UNUSUAL BILATERAL CSCR PRESENTATION. International Journal of Advanced Research. 2026;14(05):808-813. doi:10.21474/ijar01/23483
BibTeX
@article{Meena2026,
author = {Meena, Neha and Kumar, Jitendra and Gupta, Surabhi and Goynka, Yashaswi},
title = {FROM MALARIA TO MACULOPATHY: AN UNUSUAL BILATERAL CSCR PRESENTATION},
journal = {International Journal of Advanced Research},
year = {2026},
volume = {14},
number = {05},
pages = {808--813},
doi = {10.21474/ijar01/23483}
}
EUVIMED